Decatur Capital Management, Inc. Gilead Sciences, Inc. Transaction History

Decatur Capital Management, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 28, 2021	SELL	$56.65 - $64.55 $4.43 Million - $5.05 Million	-78,233 Closed	0 $0
Q3 2020 Nov 03, 2020	BUY	$62.1 - $78.08 $927,774 - $1.17 Million	14,940 Added 23.6%	78,233 $4.94 Million
Q2 2020 Aug 04, 2020	BUY	$72.34 - $84.0 $911,556 - $1.06 Million	12,601 Added 24.86%	63,293 $4.87 Million
Q1 2020 May 07, 2020	SELL	$62.63 - $80.22 $810,995 - $1.04 Million	-12,949 Reduced 20.35%	50,692 $3.79 Million
Q4 2019 Jan 21, 2020	SELL	$61.62 - $67.78 $2.34 Million - $2.57 Million	-37,949 Reduced 37.36%	63,641 $4.14 Million

Q3 2019 Oct 11, 2019	SELL	$62.51 - $69.0 $2.46 Million - $2.72 Million	-39,425 Reduced 27.96%	101,590 $6.44 Million
Q2 2019 Jul 24, 2019	SELL	$61.87 - $69.38 $201,139 - $225,554	-3,251 Reduced 2.25%	141,015 $9.53 Million
Q1 2019 Apr 23, 2019	BUY	$62.53 - $70.05 $2.43 Million - $2.72 Million	38,866 Added 36.87%	144,266 $9.38 Million
Q4 2018 Feb 13, 2019	BUY	$60.54 - $79.0 $6.38 Million - $8.33 Million	105,400 New	105,400 $6.59 Million

1,885

8.71M

8.02M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $85.7B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Decatur Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Decatur Capital Management, Inc. with notifications on news.